Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX07 in Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma
NCT05238363Phase 2Unknown
- Sponsor
- Henlius
- Start
- Jun 2022
- Primary completion
- May 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pimurutamab in cutaneous squamous cell carcinoma (cSCC), sponsored by Henlius. Primary endpoints: Progression-Free Survival up to 2 years and Objective Response Rate up to 2 years. Status: unknown.
02
Drugs
pimurutamab
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on NCT05238363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05238363.